Overview
- Moderna’s investor day that drove a roughly 13% stock jump on June 26 presented a reorganized pipeline and stronger commercial planning that traders said justified the rally.
- The company announced mRNA‑6007, its first in vivo CAR‑T program targeting B‑cell autoimmune diseases, and said clinical development is scheduled to begin in 2027.
- Analysts and commentators reacted with mixed optimism as Jefferies kept a Hold rating with a $53 target while Piper Sandler raised its target to $77 and CNBC’s Jim Cramer called the stock “investable” but urged caution.
- Near‑term value is focused on an FDA decision for Moderna’s seasonal flu candidate set for August 5, 2026 and several late‑stage oncology readouts expected in late 2026 that could materially affect revenue prospects.
- Management has centralized R&D, manufacturing and commercial teams and hired commercial leadership to prepare for multiple launches, which could change how patients access mRNA vaccines and therapies and alter Moderna’s revenue mix over the next two years.